Literature DB >> 32857986

Mechanistic Studies of the Multiple Myeloma and Melanoma Cell-Selective Toxicity of the Rpn13-Binding Peptoid KDT-11.

Paige Dickson1, Scott Simanski1, John Maina Ngundu1, Thomas Kodadek2.   

Abstract

We previously reported a peptoid ligand for the proteasomal ubiquitin receptor Rpn13 called KDT-11 and demonstrated that this compound is toxic to multiple myeloma cells, but not non-malignant cells. Here, we show that KDT-11 decreases the viability of a variety of cancer cell lines, especially melanomas and various blood cancers. The peptoid induces selective G1 cell-cycle arrest, resulting in eventual apoptosis. While KDT-11 does not antagonize any of the known protein-protein interactions involving Rpn13, the peptoid inhibits the ability of Rpn13 to stimulate the activity of an associated deubiquitylase Uch37/UCHL5 in vitro, suggesting a high level of Uch37 activity might be important for cancer cell proliferation. However, a variety of experiments in SK-MEL-5 melanoma cells suggest that KDT-11's cytotoxic effects are mediated by interactions with proteins other than Rpn13.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Rpn13; Uch37; cancer; cell cycle; combinatorial chemistry; multiple myeloma; peptoid; proteasome

Mesh:

Substances:

Year:  2020        PMID: 32857986      PMCID: PMC7680388          DOI: 10.1016/j.chembiol.2020.08.008

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  33 in total

Review 1.  Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes.

Authors:  Francisca E Reyes-Turcu; Karen H Ventii; Keith D Wilkinson
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

2.  Proteasome subunit Rpn13 is a novel ubiquitin receptor.

Authors:  Koraljka Husnjak; Suzanne Elsasser; Naixia Zhang; Xiang Chen; Leah Randles; Yuan Shi; Kay Hofmann; Kylie J Walters; Daniel Finley; Ivan Dikic
Journal:  Nature       Date:  2008-05-22       Impact factor: 49.962

3.  Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1.

Authors:  Tingting Yao; Ling Song; Wei Xu; George N DeMartino; Laurence Florens; Selene K Swanson; Michael P Washburn; Ronald C Conaway; Joan Weliky Conaway; Robert E Cohen
Journal:  Nat Cell Biol       Date:  2006-08-13       Impact factor: 28.824

4.  A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells.

Authors:  Darci J Trader; Scott Simanski; Thomas Kodadek
Journal:  J Am Chem Soc       Date:  2015-05-08       Impact factor: 15.419

5.  Knockdown of the novel proteasome subunit Adrm1 located on the 20q13 amplicon inhibits colorectal cancer cell migration, survival and tumorigenicity.

Authors:  Wei Chen; Xiao-Tong Hu; Qing-Lan Shi; Fu-Biao Zhang; Chao He
Journal:  Oncol Rep       Date:  2009-02       Impact factor: 3.906

6.  Regulators of the proteasome pathway, Uch37 and Rpn13, play distinct roles in mouse development.

Authors:  Amin Al-Shami; Kanchan G Jhaver; Peter Vogel; Carrie Wilkins; Juliane Humphries; John J Davis; Nianhua Xu; David G Potter; Brenda Gerhardt; Robert Mullinax; Cynthia R Shirley; Stephen J Anderson; Tamas Oravecz
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

7.  ADRM1 gene amplification is a candidate driver for metastatic gastric cancers.

Authors:  Seok Hoon Jang; Jun Won Park; Hyo Rim Kim; Je Kyung Seong; Hark Kyun Kim
Journal:  Clin Exp Metastasis       Date:  2014-06-27       Impact factor: 5.150

8.  Characterization of a novel myeloma cell line, MM.1.

Authors:  R E Goldman-Leikin; H R Salwen; C V Herst; D Variakojis; M L Bian; M M Le Beau; P Selvanayagan; R Marder; R Anderson; S Weitzman
Journal:  J Lab Clin Med       Date:  1989-03

9.  Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.

Authors:  Marlena S Fejzo; Judy Dering; Chuck Ginther; Lee Anderson; Lilian Ramos; Christine Walsh; Beth Karlan; Dennis J Slamon
Journal:  Genes Chromosomes Cancer       Date:  2008-10       Impact factor: 5.006

10.  Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.

Authors:  Rosie T Jiang; Anna Yemelyanova; Deyin Xing; Ravi K Anchoori; Jun Hamazaki; Shigeo Murata; Jeffrey D Seidman; Tian-Li Wang; Richard B S Roden
Journal:  J Ovarian Res       Date:  2017-08-07       Impact factor: 4.234

View more
  4 in total

1.  Physical and Functional Analysis of the Putative Rpn13 Inhibitor RA190.

Authors:  Paige Dickson; Daniel Abegg; Ekaterina Vinogradova; Junichiro Takaya; Hongchan An; Scott Simanski; Benjamin F Cravatt; Alexander Adibekian; Thomas Kodadek
Journal:  Cell Chem Biol       Date:  2020-08-27       Impact factor: 8.116

Review 2.  Proteasome interaction with ubiquitinated substrates: from mechanisms to therapies.

Authors:  Xiang Chen; Zaw Min Htet; Erika López-Alfonzo; Andreas Martin; Kylie J Walters
Journal:  FEBS J       Date:  2020-12-11       Impact factor: 5.622

3.  26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and Therapy.

Authors:  Andres J Rubio; Alfonso E Bencomo-Alvarez; James E Young; Vanessa V Velazquez; Joshua J Lara; Mayra A Gonzalez; Anna M Eiring
Journal:  Cells       Date:  2021-09-11       Impact factor: 6.600

4.  Structure-guided bifunctional molecules hit a DEUBAD-lacking hRpn13 species upregulated in multiple myeloma.

Authors:  Xiuxiu Lu; Venkata R Sabbasani; Vasty Osei-Amponsa; Christine N Evans; Julianna C King; Sergey G Tarasov; Marzena Dyba; Sudipto Das; King C Chan; Charles D Schwieters; Sulbha Choudhari; Caroline Fromont; Yongmei Zhao; Bao Tran; Xiang Chen; Hiroshi Matsuo; Thorkell Andresson; Raj Chari; Rolf E Swenson; Nadya I Tarasova; Kylie J Walters
Journal:  Nat Commun       Date:  2021-12-16       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.